跳至主要内容
临床试验/NCT03939065
NCT03939065终止不适用

Sensor Augmented Pump (SAP) Therapy for Inpatient Cystic Fibrosis Related Diabetes (CFRD) Management

University of Colorado, Denver2 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2020年6月12日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
1
试验地点
2
主要终点
Differences in CGM percent time over 140 mg/dl

研究概览

简要总结

This research proposes a pilot study using the combination of continuous glucose monitor (CGM) and insulin pump therapy, also known as sensor augmented pump (SAP) therapy, for cystic fibrosis related diabetes (CFRD) management in the inpatient setting, with the aim of improving glycemic control.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
8 Years 至 25 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥8 years
  • Confirmed diagnosis of CF by consensus guidelines [50]
  • Diagnosis of CFRD based on American Diabetes Association and CFF criteria [51]
  • Admission for pulmonary exacerbation

排除标准

  • Known type 1 or type 2 diabetes, monogenic diabetes (MODY)
  • Critical illness requiring admission to the intensive care unit
  • Admission for indications other than pulmonary exacerbation (ex. Distal intestinal obstructive syndrome, surgery)

结局指标

主要结局

Differences in CGM percent time over 140 mg/dl

时间窗: through study completion, up to 3 weeks

Differences in percent time \>140 mg/dl on CGM between groups

次要结局

  • Change in Pulmonary Function(baseline and 1 week)
  • Weight change(baseline and 1 week)
  • Statstrip glucose(through study completion, up to 3 weeks)
  • Circulatory markers of inflammation(baseline and 1 week)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验